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In APECED, the key abnormality is in the T cell defect that may lead to tissue destruc-
tion chieﬂy in endocrine organs. Besides, APECED is characterized by high-titer antibodies
against a wide variety of cytokines that could partly be responsible for the clinical symp-
toms during APECED, mainly chronic mucocutaneous candidiasis, and linked to antibodies
against Th17 cells effector molecules, IL-17 and IL-22. On the other hand, the same anti-
bodies, together with antibodies against type I interferons may prevent the patients from
other immunological diseases, such as psoriasis and systemic lupus erythematous. The
same effectorTh17 cells, present in the lymphocytic inﬁltrate of target organs of APECED,
could be responsible for the tissue destruction. Here again, the antibodies against the cor-
responding effector molecules, anti-IL-17 and anti-IL-22 could be protective.The occurrence
of several effector mechanisms (CD4+ Th17 cell and CD8+ CTL and the effector cytokines
IL-17 and IL-22), and simultaneous existence of regulatorymechanisms (CD4+Treg and anti-
bodies neutralizing the effect of the effector cytokines) may explain the polymorphism of
APECED. Almost all the patients develop the characteristic manifestations of the complex,
but temporal course and severity of the symptoms vary considerably, even among siblings.
The autoantibody proﬁle does not correlate with the clinical picture. One could speculate
that a secondary homeostatic balance between the harmful effector mechanisms, and the
favorable regulatory mechanisms, ﬁnally deﬁne both the extent and severity of the clini-
cal condition in the AIRE defective individuals. The proposed hypothesis that in APECED,
in addition to strong tissue destructive mechanisms, a controlling regulatory mechanism
does exist, allow us to conclude that APECED could be treated, and even cured, with
immunological manipulation.
Keywords: AIRE, APECED, endocrine disorders, interleukin 17, interleukin 22, IPEX,T regulatory cells
INTRODUCTION
Autoimmune polyendocrinopathy syndrome type 1 (APS-1) or
autoimmune polyendocrinopathy–candidiasis–ectodermal dys-
trophy syndrome (APECED; OMIM 240300) is a rare recessively
inherited disorder (Perheentupa, 2002; Betterle and Zanchetta,
2003; Perheentupa, 2006; Husebye et al., 2009). It is caused by
mutations in the autoimmune regulator (AIRE) gene located
on locus 21q22.3 (Bjorses et al., 1996; Nagamine et al., 1997;
The Finnish–German APECED Consortium, 1997). APECED
displays a worldwide distribution, but speciﬁc clusters of high
prevalence of the disease are observed among Finns (1:25,000;
Abbreviations: AADC, aromatic L-amino acid decarboxylase; AD,Addison’s disease;
AE, autoimmune enteropathy; APS-1, autoimmune polyendocrinopathy syn-
drome type 1; APECED, autoimmune polyendocrinopathy–candidiasis–ectodermal
dystrophy; CMC, chronic mucocutaneous candidiasis; EECs, enteroendocrine
cells; GI, gastro-intestinal; HP, hypoparathyroidism; IPEX, immune dysregula-
tion, polyendocrinopathy, enteropathy and X-linked; IF, intrinsic factor; IL-1,
interleukin-1; IL-17, interleukin-17; IL-22, interleukin-22; mTECs, thymic
medullary epithelial cells; NALP-5, NACHT leucine-rich-repeat protein 5; PE,
promiscuous expression; PTH, parathormone; SLE, systemic lupus erythemato-
sus; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; TRIMs, tripartite
motif-containing proteins; TSA, tissue-speciﬁc antigens.
Ahonen et al., 1990) and Sardinians 1 (1:14,500; Rosatelli et al.,
1998; Meloni et al., 2012). It is characterized by the variable asso-
ciation of autoimmune endocrine [hypoparathyroidism (HP),
Addison’s disease (AD), hypothyroidism, gonadal insufﬁciency,
insulin-dependent diabetes mellitus, atrophic gastritis, and Bier-
mer’s disease] and non-endocrine disorders (keratitis, malabsorp-
tion, vitiligo, and alopecia areata) and a speciﬁc predisposition to
chronic mucocutaneous candidiasis (CMC). A deﬁnite diagnosis
of APECED is made upon one of the following criteria: (i) the
presence of at least two of three major clinical features: CMC, HP,
and AD, or (ii) one disease component if a sibling has already a
deﬁnite diagnosis, or (iii) disease-causing mutations in both alle-
les of the AIRE gene. However, APECED being highly variable
in its presentation, the classical triad may be complete only after
years of evolution and diagnose may be therefore missed. Besides,
APECED may appear during adolescence or in the young adult
(Husebye et al., 2009). Therefore, criteria for a probable APECED
have been deﬁned as follows: (i) presence of one of CMC, HP,
AD (before 30 years of age) and at least one of the minor compo-
nents chronic diarrhea, keratitis, periodic rash with fever, severe
constipation, autoimmune hepatitis, vitiligo, alopecia, enamel
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hypoplasia, (ii) any component and anti-interferon antibodies, or
(iii) any component and antibodies against NACHT leucine-rich
repeat protein 5 (NALP5),AADC, tryptophan hydroxylase (TPH),
or TH (Husebye et al., 2009).
FROM CIRCULATING AUTOIMMUNE ANTIBODIES
TO AIRE, FOXP3, APECED, AND IPEX
Our knowledge of the nature of the condition now called APS-1
or APECED has increased simultaneously with the general devel-
opment of immunology and autoimmunity. Since the condition
was clearly deﬁned in the end of 1950s and early 1960s, the char-
acteristic clinical picture, the immunological abnormalities and
the relationship to other autoimmune endocrine diseases were
deﬁned in late 1960s and early 1970s. Furthermore, the genetics
of APECED, and the fact that the syndrome was caused by a reces-
sive gene defect – as opposed to the HLA-linked genetics seen in
the other solitarily occurring endocrine diseases – were character-
ized in the 1980s and the target antigens in the organs affected by
APECED were molecularly deﬁned in 1990s. A landmark stage in
the study of APECED was reached in 1997, when the long sought
APECED gene was cloned by two independent groups (Nagamine
et al., 1997; The Finnish–German APECED Consortium, 1997).
Finally, a new phase in APECED research occurred during the
ﬁrst decennium of 2000, when the autoantibodies toward soluble
mediators if immune response were characterized (Meager et al.,
2006; Kisand et al., 2011).
The notion that several diseases affecting endocrine organs and
earlier deﬁned as idiopathic, were in fact caused by an autoim-
mune response toward self antigens, became apparent when novel
immunologicalmethods became available in 1950s and early 1960s
(Blizzard et al., 1963). The association of the three conditions,
candidiasis, HP, and AD that were later judged to be the hall-
marks of APECED was clearly stated by the groups of Blizzard and
Maclaren (Blizzard et al., 1963; Brun, 1978; Neufeld et al., 1981).
These groups also deﬁned two clearly distinct syndromes with
several associated autoimmune diseases: autoimmune polyglan-
dular syndrome type 1 (PGS-1) and polyglandular syndrome type
2 (PGS-2). The nomenclature was later changed to APS-1 and
APS-2, and the former further to APECED (Ahonen et al., 1990;
Perheentupa, 2002, 2006; Betterle and Zanchetta, 2003).
Pioneering studies in this ﬁeld were made especially with the
use of immunohistochemistry, demonstrating antibodies react-
ing with gastric parietal cells in chronic gastritis (Walder et al.,
1963; Irvine et al., 1965) and intrinsic factor (IF) in pernicious
anemia (Schwartz, 1961; Jeffries et al., 1962), with thyroid epithe-
lial cells in various forms of thyroid diseases (Witebsky et al., 1957;
Irvine et al., 1962; Doniach and Roitt, 1964), with the beta cells of
Langerhans islands in diabetes mellitus (Kaldany, 1979; Bottazzo
et al., 1980), and adrenal cortical cells in AD (Blizzard et al., 1962).
Blizzard’s group noticed that the two polyglandular syndromes,
APS-1 andAPS-2, differed in their HLA haplotypes (Neufeld et al.,
1981). Further studies on the HLA haplotypes revealed that the
genetic basis of APS-2, but also of the other isolated forms of
endocrine autoimmune diseases found in APS-1, were in the HLA
haplotype of the patients. In contrast, APS-1 was shown not to be
linked to HLA, and studies with large patient material, collected
by Perheentupa’s group in Finland, clearly stated that APS-1 was
linked to a recessively inherited gene defect (Ahonen et al., 1990;
Perheentupa, 2002, 2006). The autoimmune endocrinopathies
could thus be grouped on the basis of their genetic background
in two distinct categories: those linked to HLA variation and the
one, APS-1 caused by a single mutated gene (Table 1). At that
stage, however, the responsible gene, the APECED gene, was not
yet identiﬁed. Once identiﬁed, the APECED gene was renamed
as AIRE in 1997 (Nagamine et al., 1997; The Finnish–German
APECED Consortium, 1997).
Another immunopathy, termed originally as autoimmune
enteropathy (AIE) and later identiﬁed as immune dysregula-
tion, polyendocrinopathy, enteropathy and X-linked (IPEX), was
described in the 1980s and 1990s (Powell et al., 1982). This dis-
order was later shown to be caused by a defect in a single gene,
FOXP3 (Bennett et al., 2000). IPEX andAPECEDare two examples
of immune deﬁciency diseases disclosing both disturbed tolerance
and autoimmune phenomena (Moraes-Vasconcelos et al., 2008).
Traditionally, reviews tend to associate both IPEX and APECED
because of common features. However, both clinical manifesta-
tions and predisposition to infections are rather different when
comparing both diseases (Moraes-Vasconcelos et al., 2008).
AIRE GENE, MUTATIONS, AND MECHANISM OF ACTION
AIRE is expressed in thymus, lymph nodes, and fetal liver, and
encodes a protein with two putative zinc ﬁngers and other motifs
suggestive of a transcriptional regulator (Nagamine et al., 1997;
The Finnish–German APECED Consortium, 1997). The AIRE
gene, approximately 13 kb in length, contains 14 exons that
encode a polypeptide of 545 amino acids. The AIRE protein func-
tions as a transcription factor (Fierabracci, 2011; Gardner et al.,
2009). AIRE is expressed in the thymic medullary epithelial cells
(mTECs, Figure 1) and in cells of the monocyte/dendritic cell
lineage (Kogawa et al., 2002). mTECs through the expression of
MHC class II express a wide array of tissue-restricted antigens
(TRAs) derived from different organs in the body. TRAs include
self-proteins with patterns of expression restricted to a single or
small handful of organs. Thymic expression of TRA serves as an
important source of self-antigens to allow the negative selection
of autoreactive T cells. Collectively, mTEC and thymic mono-
cyte/dendritic cells play a crucial role in establishing self-tolerance
by eliminating autoreactive T cells (negative selection) and/or
by producing immunoregulatory FOXP3+ T cells, which prevent
CD4+ T cell-mediated organ-speciﬁc autoimmune diseases. Col-
lectively, several studies in mouse and man have shown that AIRE
regulates thymic expression of several genes of ectopic peripheral
proteins including many TRAs. Thus, AIRE dysfunction leads to
a decrease in the expression of TRAs in the thymus, and con-
sequently, autoreactive T cell clones escape into the periphery
(Derbinski et al., 2005; Moraes-Vasconcelos et al., 2008; Gardner
et al., 2009; Fierabracci, 2011)
The most common AIRE mutation, the “Finnish mutation,”
R257X, affects 82% of Finnish APECED alleles (Nagamine et al.,
1997; The Finnish–German APECED Consortium, 1997). Inter-
estingly, this mutation occurs also in 70% of the Russian APECED
patients studied (Orlova et al., 2010). The same mutation, R257X
was also detected in Swiss patients on a different haplotype with
closely linked polymorphic markers (Nagamine et al., 1997) and in
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FIGURE 1 | Medullary epithelia cells in thymus, expressing the AIRE
proteins (reddish brown), in close vicinity of the Hassall’s corpuscles
(HC) where auto-reactiveT cells are thought to be destroyed. Note cell
debris in HC. Magniﬁcation 1:40. AIRE was demonstrated with speciﬁc
monoclonal antibody at 1:2,000 dilution.
northern ItalianAPECED patients. NonsensemutationR139Xwas
found as the predominant haplotype among Sardinian patients
(18/20 independent alleles; Rosatelli et al., 1998). Other hotspots
have been identiﬁed such as the Y85C missense mutation in
an isolated Iranian Jewish community (Zlotogora and Shapiro,
1992; Björses et al., 2000). A 13-bp deletion in exon 8 [1085–
1097(del)] is ubiquitous and can be found in Norwegians, but
also Anglo–Saxons descendant (Zlotogora and Shapiro, 1992) and
southAmericans (Moraes-Vasconcelos et al., 2008). Today, over 60
different mutations have been described throughout the coding
region of AIRE (Akirav et al., 2011).
CLINICAL PICTURE OF APECED
The clinical picture of APECED is characterized by sequentially
occurring diseases, with great variation among the patients as
to the severity and time course of the various conditions. In
most cases, the affected individual starts suffering from CMC
in early infancy or childhood. In most cases, the next organs to
be affected are the parathyroid glands, followed by AD and at
puberty, hypogonadism mainly in female teens or young adults.
Additional clinical features are less common, and include dia-
betes type I, hypothyroidism, atrophic gastritis with or without
pernicious anemia (Biermer’s disease), cutaneous manifestations
(alopecia areata, vitiligo, transient skin rash during fever episodes,
non-infectious nail dysplasia), ocular symptoms (keratoconjunc-
tivitis, dry eye, iridocyclitis, cataract, retinal detachment, and
optic atrophy;Merenmies andTarkkanen,2000), enamel dysplasia,
hyposplenism/asplenia (implying vaccination against Streptococ-
cus pneumonia, Haemophilus inﬂuenzae, and Hepatitis B as well as
antibiotic prophylaxis), autoimmune hepatitis, tubulo-interstitial
nephritis, or organized pneumonitis. Involvement of the gastro-
intestinal (GI) tract may be responsible for chronic diarrhea,
constipation, and malabsorption leading sometimes to malnu-
trition. GI involvement is difﬁcult to assess as it can be due to
numerous various causes that may be associated or follow each
other during the life of the patients.
CANDIDIASIS
Chronicmucocutaneous candidiasis infection byCandida albicans
is one of the major characteristic of APECED, usually one of ﬁrst
symptoms and most likely the most disabling features of APECED.
CMC is naturally not speciﬁc forAPECEDbut any childwithCMC
should be suspected of APECED. According to the Finnish experi-
ence, almost all adults with APECED display symptoms of CMC,
up to 70% of the patients at the age of 10, up to 94% at age of 20,
and 97% at the age of 30 (Perheentupa, 2002, 2006; Betterle and
Zanchetta, 2003; Husebye et al., 2009). However, the course and
severity vary widely. Oral candidiasis affects the tongue, the buccal
mucosa, the gingival, and the pharynx. It ranges in severity from
mild form with redness, soreness, angular cheilitis, pseudomem-
branous lesions, erosions, ulceration and pain to severe chronic
inﬂammation with dysphagia, and development of hyperkera-
totic plaques. In the absence of active antimycotic treatment and
careful follow-up, chronic oral candidiasis may lead to the devel-
opment of squamous cell carcinoma with potential lethality by
metastatic dissemination. Candida esophagitis has been reported
to affect 15–22% of the patients (Perheentupa, 2006; Kisand et al.,
2011)with painwhile swallowing, retrosternal pain, anddysphagia
(Ahonen et al., 1990; Husebye et al., 2009). Chronic esophagi-
tis can lead to local stricture and exceptional esophageal cancer
(Rautemaa et al., 2007).
Intestinal candidiasis may cause chronic diarrhea. It should
be stressed that esophageal and intestinal candidiasis may occur
without any active oral candidiasis. Genital candidiasis affects
mainly women with pruritus and vaginal whitish discharge
while genital candidiasis seems less frequent in males, pos-
sibly underreported due to discrete signs of balanitis. Lastly,
Candida may affect the nails with chronic paronychia and ony-
chomycosis (Collins et al., 2006). Fingernails are more commonly
affected than toenails and the thumbs are the commonest digit
affected. This can be explained as infection occurs during the
“thumbsucking” period. Management of candidiasis in APECED
patients implies an excellent oral hygiene with a careful and
regular dental follow-up. Candidiasis should be treated aggres-
sively with antimicrobial therapy and regular prophylaxis should
be given.
Any clinically suspicious, chronic thickening or erosion of the
mucosa that does not heal shouldbebiopsied to rule out a potential
underlying lesion of squamous cell carcinoma. Any difﬁculties
in swallowing or eating or retrosternal pain should prompt to
perform esophagoscopy (Rautemaa et al., 2007).
HYPOPARATHYOIDISM
Hypoparathyroidism is one of the ﬁrst endocrine features of
APECED. Symptoms are related to hypocalcemia, muscle cramps,
paresthesia, clumsiness, seizures, and diarrhea. The diagnosis is
simply based on blood calcium, phosphorus, and parathormone
(PTH) levels: hypocalcemia, hyperphosphatemia, inadapted nor-
mal/low PTH without any kidney failure. It is considered that
APECED should be systematically considered in cases of primary
HP (Husebye et al., 2009). Antibodies against NALP5 as well as
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against the calcium-sensing receptor of parathyroid epithelial cell
have been identiﬁed in APECED patients (Gavalas et al., 2007;
Kemp et al., 2009, 2010). Patients who are free of HP need an
annual monitoring of blood calcium and phosphorus levels. Man-
agement of HP relies on daily oral supplementation of vitamin D
derivatives and calcium.
GASTRITIS AND PERNICIOUS ANEMIA
Chronic gastritis, with or without concomitant pernicious anemia
belongs to the APECED complex but is found only in a fraction of
cases. In non-APECED population, two types of chronic gastritis
occur, divided by Strickland into type A and B gastritis. Type A
gastritis was known to be caused by autoimmunity while the B
gastritis was suspected to be the results of environmental factors.
In early 1980s, it was shown by Warren and Marshall (1984) that
themajor environmental factorwas in fact a chronic infectionwith
Helicobacterium pylori.
The type A chronic gastritis, with and without pernicious ane-
mia that occur in non-APECED individuals, is clearly linked
to certain HLA risk haplotypes, in analogy to isolated AD. In
APECED patients, the chronic gastritis differs from the above
also in time of occurrence and the speed of the progression. In
non-APECED patients, the time needed for progression from the
early stage of gastritis, the superﬁcial form to diffuse gastritis, to
atrophic gastric and to full gastric atrophy is a slow process, taking
up several decennia. Also, the process usually starts in the adult
life. In contrast, an APECED-associated gastritic process is much
faster and can start in the ﬁrst decennium of life. Thus, one of
the authors of this review was able to follow such a gastric process
in two 8-year-old girls with sequential gastric biopsies and could
see how, within the time period of only 2 months, the superﬁcial
process lead to complete gastric atrophy of the fundus and corpus
(K. Krohn, personal experience).
The target molecule for the parietal cell antibodies were shown
to be the sodium-potassium channel molecule of the parietal cells
on corpus and fundal part of the stomach (Karlsson et al., 1988).
In antral gastritis, the antigen are the gastrin-producing cells
(Uibo and Krohn, 1984).
Pernicious anemia is the end stage of the gastric immunological
destruction, caused partly by the lack of IF, that in addition to the
hydrochloric acid is the main product of parietal cells, but also by
the autoantibodies recognizing this vitamin B12-binding protein.
There are two types of antibodies to IF: one blocking vitamin
B12 binding to IF and another type, binding to the IF molecule
without interfering with vitamin B12 binding (Toh et al., 1997).
Both antibody types prevent the binding of IF to its receptor on
the ileal mucosa and subsequent translocation of the vitamin B12
from ileum to circulation.
ADDISON’S DISEASE
Adrenocortical failure or AD, described by Thomas Addison in
the ninetieth century, is considered one of the three hallmarks
of APECED, but it occurs also as a solitary disease, or as part of
the APS-2 complex. Today, in western word, most cases of AD
are caused by autoimmunity, but adrenal cortical destruction and
subsequent cortical failure can be caused by several other factors,
notably by secondary tuberculosis or other chronic infections. In
retrospect, the cases described by Thomas Addison were most
likely caused by tuberculosis.
The clinical signs and symptoms of AD are mostly similar in
APECED and in solitary AD as well as in APS-2 complex. These
include decreased levels of gluco- and mineralocorticoids and ele-
vated ACTH concentrations. The most severe consequence of AD
is the life-threatening Addisonian crisis, characterized by general
fatigue, dizziness, diarrhea, and death, if the patient is not quickly
substituted with corticosteroids, mainly hydrocortisol.
Autoantibodies to adrenal cortex are the characteristic
immunological feature in AD, be it part of APECED or APS-2
or the solitary form. These antibodies can be easily demonstrated
by immunoﬂuorescence. However, in APECED, but not in the
other forms of AD, the autoantibodies are precipitating, and this
phenomenon can be demonstrated by Ouchterlony’s immunod-
iffusion (Andrada et al., 1968; Krohn et al., 1974; Heinonen et al.,
1976). In immunodiffusion with APECED serum against adrenal
homogenate three precipitating lines were observed, and one of
these were shown to represent a mitochondrial antigen while the
two others were microsomal.
The nature of the adrenal cortical autoantigens were revealed
in early 1990s and shown to be the three main steroidogenic
enzymes, P450c17, P450c21, and P450scc (Krohn et al., 1974;
Winqvist et al., 1993; Uibo et al., 1994a,b). These three enzymes
were also shown to be the ones that could be precipitated
by immunodiffusion. The autoantibodies against these three
steroidogenic enzymes clearly distinguish the three clinical con-
ditions with adrenal failure: antibodies to all three can be found
only in APECED, while in solitary AD and in APS-1, only anti-
bodies to P450c21 are seen. Furthermore, in non-autoimmune
AD, caused by tumors or chronic infections, such antibodies
do not occur.
GONADAL FUNCTIONS
Autoimmune oophoritis is responsible for an ovarian insufﬁciency
that may be dramatic for female patients as insufﬁciency starting
in teenagers and young adults. Patients may have either a pri-
mary amenorrhea with no or arrested puberty. Other patients
develop prematuremenopause. The diagnosis is conﬁrmed by sex-
ual hormones status; elevated plasma levels of follicle stimulating
hormone (FSH) and luteinizing hormone (LH) and low estrogen
levels. Autoantibodies against side-chain cleavage enzyme have
been related to ovarian insufﬁciency (Soderbergh et al., 2004) and
also steroidogenic enzymes antibodies against cytochrome p450
21-hydroxylase (CYP21A2), cytochrome p450 17α-hydroxylase
(CYP17), and cytochrome p450 side-chain cleavage enzyme
(CYP11A1).
In female patients, hormonal substitution by estrogen needs
to be initiated during puberty. It is strongly advised not to delay
pregnancy. In case of hypogonadism, embryo donation has been
tried with success.
In males, testicular failure is less common and occurs later.
The prevalence of hypogonadism in males is three times lower
(8–28%) than in females (35–70%; Perheentupa, 2006). It leads to
clinical hypogonadism or isolated azoospermia (Husebye et al.,
2009). It has been hypothesized that the blood–testis barrier
protects the Leydig cells from an autoimmune attack. However,
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the physiopathogenic link between circulating autoantibodies and
hypogonadism is far from being clear. The two steroidogenic
enzymes, p450scc and p450c17, are the main antigens in gonadal
failure linked to APECED, but other potential antigenic targets
have been identiﬁed such as testis-expressed protein TSGA10
(Reimand et al., 2008). However, despite autoantibodies directed
against TSGA10 in 7% of the APECED patients, no correlation
could be found with gonadal failure (Reimand et al., 2008). One
should not forget that the origin of gonadal dysfunction may
be related to an authentic-speciﬁc autoimmune attack but also
be related to other hormonal dysfunction such as AD, pituitary
insufﬁciency, dysthyroidism, or diabetes for instance. Besides,
Schaller et al. (2008) suggested that lack of AIRE might affect fer-
tility by disrupting scheduled apoptosis of testicular germ cells.
In this respect, the recent hypothesis presented by Matsumoto
(2011) that the function of AIRE in thymus would not be in
the regulation of transcription but rather in the development
and differentiation of the medullary epithelial cells is of primary
interest
OTHER ENDOCRINE DISORDERS
Various other endocrine disorders have been described such dia-
betes type I mellitus, hypothyroidism, and pituitary failure, the
latter diagnosed by a growth hormone deﬁciency. The diagno-
sis and management of these conditions does not differ from
the standard guidelines for each disorder separately (Perheentupa,
2002; Betterle and Zanchetta, 2003; Husebye et al., 2009).
OTHER NON-ENDOCRINE DISORDERS
Enamel hypoplasia affect mainly permanent teeth (Perheentupa,
2006), but also deciduous teeth (Pavlic and Waltimo-Sirén, 2009).
Pavlic and Waltimo-Sirén (2009) recently suggested that an inad-
equate process of enamel formation might affect all ameloblasts
in phase. Ameloblasts have an epithelial origin with parenchy-
mal cells of endocrine origin. It is speculated that ameloblasts
or secreted protein in the extracellular matrix may be the tar-
get of autoantibodies leading to hypoplasia. Thereby, APECED
would be the ﬁrst model of dental hard tissue autoimmune disease
(Pavlic and Waltimo-Sirén, 2009).
Ocular manifestations affect 25% of the patients and include
mainly keratitis that can lead to blindness. It is assumed that the
origin of keratitis is the result of autoimmunity against corneal
epithelium (Merenmies andTarkkanen, 2000; Perheentupa, 2006).
However, to our knowledge no speciﬁc antibodies have been iden-
tiﬁed in APECED patients. Only antibodies against OBP1 have
been found in the AIRE mouse model against lacrimal glands
(DeVoss et al., 2010).
Hyposplenismor asplenia is often diagnosed upon the develop-
ment of thrombocytosis, circulatingHowell–Jolly bodies, abdomi-
nal ultrasound imagingor in case of severe S. pneumoniae infection
(Pollak et al., 2009). Destruction of the spleen inAPECEDhas been
related to an autoimmune attack against the spleen (Perheentupa,
2002, 2006; Betterle and Zanchetta, 2003; Husebye et al., 2009)
although the exactmechanismremains obscure. Again, themecha-
nisms proposed by Schaller et al. (2008) and by Matsumoto (2011)
are of interest, as AIRE expression has also been described in lym-
phoid tissue and skin. A speculative hypothesis to the evolution of
splenic atrophy could thus be disturbance of differentiation, due
to lack of AIRE expression.
Various types of GI manifestations are common in APECED
patients. These include chronic diarrhea that can be related to HP,
severe constipation. Intestinal infection by candida and giardia
especially, pancreatic insufﬁciency and autoimmune enteropa-
thy. Several autoreactive circulating antibodies directed toward
intestinal components have been described. Ekwall et al. (1998)
identiﬁed TPH as an intestinal autoantigen in APECED patients.
TPH is expressed in serotonin-producing cells in the central ner-
vous system and in the intestine. In their series of 80 patients, they
were able to relate “GI symptoms” to the presence of circulating
TPH antibodies and also to the total absence of enterochromaf-
ﬁn cells in the mucosa of small bowel. These enteroendocrine
cells (EECs) are scattered through the intestinal mucosa, from the
gastric body and antrum to the rectum. They play a key role in
growth of the gut, blood ﬂow, motility, secretion of pancreatic
enzymes, bile, and bicarbonate-rich ﬂuid (Posovszky et al., 2012).
TPH antibodies were found in 89% of the APECED patients with
GI symptoms and in 34% of those without (Ekwall et al., 1998).
Antibodies can precede clinical symptoms (Ekwall et al., 1998).
Conversely, TPH autoantibodies are absent in other inﬂamma-
tory or autoimmune intestinal diseases. Additionally, Sköldberg
et al. (2003) identiﬁed also autoantibodies against histidine decar-
boxylase expressed by EEC – like cells in the gastric mucosa. It
is noteworthy, that it is not a routine procedure to perform EECs
stainingon intestinal biopsies in case of diarrheaormalabsorption,
as stressed by Ohsie et al. (2009). Besides, several studies showed
repeatedly that EECs were lacking in the intestinal mucosa and
were related to chronic diarrhea (Padeh et al., 1997; Ward et al.,
1999; Oliva-Hemker et al., 2006; Posovszky et al., 2012).
Tubulo-interstitial nephritis, life-threatening autoimmune
bronchiolitis and other rare manifestations have also been
reported in APECED (Perheentupa, 2002, 2006; Betterle and
Zanchetta, 2003; Husebye et al., 2009). The main identiﬁed
autoantibodies are summarized in Table 2.
TREATMENT
Management of APECED relies in education of the patients to
know his disease, education of the local physician, and the
knowledge that new components of the disease may develop
during life. Psychological support is strongly recommended as
this disease impairs greatly the quality of life of the patients
(Perheentupa, 2006). Except candidiasis treatment that has been
explained previously, treatment of APECED relies mostly on hor-
mone replacement therapy according to affected organs (thyroid,
parathyroid, pancreas, etc.). In some rare and potentially lethal
situations, however, patients may require corticosteroid treatment
in association with immunosuppressive therapies. These rare sit-
uations include autoimmune hepatitis, especially its fulminant
form, which may be lethal and therefore prompt immunosup-
pressive therapy is needed (Obermayer-Straub et al., 2001). The
same is true for interstitial nephritis and bronchiolitis in associ-
ation to APECED. Immunosuppressive therapies have been also
proposed in case of severe intestinal malabsorption with efﬁcacy
(Padeh et al., 1997; Ward et al., 1999). Very recently, Rituximab,
a chimeric monoclonal antibody targeting B cell lymphocytes
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Table 2 | Main identified target of autoimmune antibodies in APECED
patients.
Diagnosis Main identified circulating autoantibodies
Addison’s disease 21 hydroxylase, 17α hydroxylase
Side-chain cleavage enzyme antibodies
(or steroid cell antibodies)
Hypoparathyroidism NALP5, Ca2+ sensing receptor
Hypothyroidism Thyroperoxydase
Thyroglobuline
Hypogonadism 17α hydroxylase
Side-chain cleavage enzyme antibodies
(or steroid cell antibodies)
Diabetes type I Glutamic acid decarboxylase 65-kDa isoform
(GAD65)
Insulin
Tyrosine phosphatase (IA2)
Pituitary insufﬁciency Tudor Domain containing protein 6 (TDRD6)
Atrophic gastritis/
Biermer’s disease
Intrinsic factor, gastric parietal cell
Intestine Glutamic acid decarboxylase 65-kDa isoform
(GAD65)
Histidine decarboxylase
Tryptophan hydroxylase
Autoimmune hepatitis Aromatic L-amino acid decarboxylase (AADC)
Cytochrome P450 1A2
Cytochrome P450 2A6
Cytochrome P450 1A1
Cytochrome P450 2B6
Vitiligo Transcription factors: SOX 9, SOX 10, aromatic
L-amino acid decarboxylase (AADC)
Alopecia areata Tyrosine hydroxylase
Nephropathy Antibody against tubular basement membrane
(Hannigan et al., 1996)
Pulmonary disease Potassium channel regulatory protein (KCNRG)
Eye OBP1*
Non-tissue speciﬁc** IFN-α, IFN-β, IFN-ω, IL-22, IL-17F, IL-17A
*Identiﬁed in a mouse model AIRE−/−.
**Main non-tissue-speciﬁc antibodies according to Kisand et al. (2011).
expressive CD20 has been successfully used in a young patient with
bronchiolitis (Popler et al., 2012). The rationale for Rituximab use
in APECED is supported by the presence of B cell inﬁltrates in the
affected organs (Gavanescu et al., 2008).
AUTOANTIBODIES TOWARD INTERFERONS AND CYTOKINES
At the beginning of this millennium, the antibody responses to
the main target organs affected in APECED, and the responsi-
ble target antigens were fairly well characterized. A new period
in APECED studies started along the publication by Meager
et al. (2006), describing high-titer antibodies to several type I
interferons in practically all APECED patients studied. This anti-
interferon response was exceptionally strong, since serum titers
up to 1:1,000,000, and clearly exceeding the titers seen against
organ-speciﬁc antigens, were found.
Furthermore, high-titer antibodies were seen against the
two main mediators secreted by Th17 cells, interleukin-17 and
interleukin-22 (IL-17 and IL-22). Responses with lower titers were
occasionally seen against other interleukins, too. In our own as
yet unpublished observations we have detected occasional high-
titer responses against several other interleukins and chemokines,
as well, but in contrast to the aforementioned responses, these
responses are not characteristic to all APECED patients but rather
occur occasionally in only a few patients.
The signiﬁcance of these novel ﬁndings are still unclear, but
some information concerning the role of IL-17/IL-22 antibod-
ies in the chronic candida infections, characteristic for APECED,
has been obtained. Th17 cells secrete IL-17 and IL-22, which
are cytokines with potent antifungal properties (Engelhardt and
Grimbacher, 2012) and the occurrence of autoantibodies against
IL-17/IL-22 were reported to closely correlate to the presence of
candida infection (Kisand et al., 2011; Engelhardt andGrimbacher,
2012). However, recent evidence points to a new interaction
between AIRE and dectin-1, a pattern-recognition receptor that
is important in antifungal innate immunity. Pedroza et al. (2012)
recently showed that AIRE participates in the dectin-1 signaling
pathway, and thus, missing AIRE activity could contribute to fun-
gal susceptibility through this pathway. Dectin-1 is expressed on
phagocytes and was recently shown to induce a non-canonical
caspase-8 inﬂammasome in response to fungal and mycobac-
terial infection (Gringhuis et al., 2012). The activation of the
dectin signaling pathway also leads to expression of IL-17 and
22 and defensins, however. Besides, other mechanisms such
Dominant-negative mutations in STAT3, gain of mutation of
STAT1, mutations in IL-17F and IL-17R may be alternate causes
of CMC (Engelhardt and Grimbacher, 2012).
The signiﬁcance of the antibody response toward interferons
and other cytokines is presently also unclear. One could speculate
that some of these antibodies against type I interferons as well as
reacting with IL-17 and IL-22 might have a protective function.
As pointed out by Waterﬁeld and Anderson (2011), antibodies to
type I interferons do not seem to lead to increased susceptibility
to viral infections. This resistance might be due to redundancy
and it has to be seen whether this anti-interferon response is
directed only toward certain members of the interferon family.
While Th17 cell response and the release of soluble IL-17 and
IL-22 are evidently necessary for the defense against mucocuta-
neous candida infection, the same cytokines have a role in the
development of psoriasis. Similarly, interferons are known to be
involved in the pathogenesis of several conditions, and one such
chronic ailment is the autoimmune diseases belonging to the sys-
temic lupus erythematosus (SLE) complex. Anti-interferon alpha
antibodies are currently being tested as a therapeutic mean against
SLE (Merrill et al., 2011). In order to be able to ﬁnd out if the
antibodies against interferons and other cytokines could have a
protective role in APECED, large APECED patient cohorts have to
be studied in order to ﬁnd out whether, e.g., psoriasis and SLE are
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signiﬁcantly less common in APECED patients than in the general
population.
The reason for the antibody response toward soluble immune
mediators is still unclear, and we do not yet know what exactly
elicits them and thus, only speculative scenarios can be presented.
It is conceivable to hypothesize, however, that the tissue destruc-
tion preceding the failure of the endocrine organs may have a
role. Tissue destruction, be it caused by trauma, viral infec-
tion or autoimmune attack, would probably lead not only to
the release of potential tissue-speciﬁc autoantigens and thus, to
autoantibody formation against these proteins, but could also
lead to an inﬂammatory response and production of several
mediators of inﬂammation. One key group of molecules in this
respect is the acute phase proteins, notably those belonging to the
IL-1 group.
It is generally believed that the destruction of the endocrine
organs in APECED is caused by the autoreactive CD8+ cyto-
toxic T cells, although deﬁnitive evidence for this mechanism is
still lacking (Betterle and Zanchetta, 2003; Moraes-Vasconcelos
et al., 2008). This hypothesis is reinforced by the examination of
microscopic examinations of samples, sometimes obtained post-
mortem. Indeed, parathyroid, adrenal glands, or ovaries pathology
disclosed also atrophy and lymphocytic inﬁltration that suggest
lymphocytic aggression of the organs leading to atrophy and
dysfunction (Betterle and Zanchetta, 2003). This is also stressed,
indirectly, by the analysis of theAIRE-deﬁcient mouse model, who
develop also a lymphocytic inﬁltration in some inner organs along
with atrophy (Ramsey et al., 2002).
However, cell destruction caused by an immune response
against the endocrine organ would in fact lead to a similar sit-
uation that is thought to happen in viral infections. In fact, several
autoimmune diseases, such as diabetes type I or chronic autoim-
mune liver diseases are thought to be a consequence of preceding
viral infection: enterovirus infection in the case of diabetes type
I and hepatitis B in the case of chronic active hepatitis. In viral
infections, a speciﬁc group of intracellular regulatory molecules,
TRIMs (tripartite motif-containing proteins), have been shown to
have a key role in eliciting an autoimmune or auto inﬂammatory
consequence (Jefferies et al., 2011).
The TRIM protein family is a form of RING domain containing
E3 ligases and they exert a variety of biological functions, related
to immunity and inﬂammation (Jefferies et al., 2011). Speciﬁcally,
of the more than 20 different TRIM proteins, some seem to up-
regulate the expression of type I interferons and proinﬂammatory
cytokines, notable interleukin-1beta (IL-1beta). Furthermore, the
same mediators of immune response and inﬂammation are in
some cases known to up-regulate the expression of TRIMs. Thus,
a vicious circle can theoretically occur and this in turn could
lead to autoimmunity. So far, overexpression of TRIMs, or an
autoimmune response toward them, has been shown to be linked
to autoimmune and autoinﬂammatory processes in Sjögren’s
syndrome or rheumatoid arthritis (Jefferies et al., 2011).
Presently, we have no information how the occurrence of
autoantibodies toward the interferons and other mediators of
immune response might affect the aforementioned vicious circle,
but it is conceivable to speculate that such an antibody response
could have an balancing effect. One could thus form a hypothesis,
that in APECED, the primary defect outside thymus, where the
autoreactive T cells are not destroyed,would be the cell destruction
of the endocrine organs by cell-mediated immune response, fol-
lowed by release of cellular components taken up by professional
antigen presenting cells and further stimulating the activation of
CD4+ Th-cells and ﬁnally resulting in an autoantibody response
to these organ-speciﬁc antigens. However, simultaneous overex-
pression of TRIMs and subsequent up-regulation of a variety of
soluble mediators of immune response and inﬂammation, such as
interferons and members of the IL-1 family would lead to autoan-
tibody formation also against these cytokines. Lastly, one reason
for the break of tolerance to immune mediators, and subsequent
production of autoantibodies could be related the fact that AIRE
expression seems to occur, in addition to thymic epithelial cells also
outside thymus, notably in dendritic cells, that normally express
also such mediators (Heath and Carbone, 2009)
The consequences of such cytokine-directed antibody response
are still an open question. In case of the Th17 type interleukins
(IL-17 and IL-22) there is convincing evidence that such antibod-
ies are linked to the CMC. However, at least in some cases, the
antibodies may have a balancing, down-regulating effect on the
expression of the corresponding biologically active molecules but
also, by regulating the immune response to target organs. Thus,
it is possible to presume, that especially the antibodies to type I
interferonsmight have a protective effect, as some chronic immune
diseases, such as psoriasis and SLE, are rare or non-existing among
APECED patients.
CELL-MEDIATED IMMUNE RESPONSES
Although it is now a generally accepted view that the consequence
of the AIRE defect in APECED will lead to the escape of the poten-
tially autoreactive T cells, there is in fact rather little direct evidence
to show that the tissue destruction in the endocrine organs affected
in APECED is caused by cytotoxic CD8+ T cells. Furthermore,
most studies describing the phenotype of the lymphocytes inﬁl-
trating affected organs is not from APECED patients directly, but
from patients suffering of solitary lesions that are similar to the
ones seen in APECED, such as solitary AD or diabetes. However,
the solitary endocrine diseases, such as isolated thyroid disease
or AD are remarkably similar in their clinical picture as well as
immunological ﬁndings as those of APECED. Thus, in solitary
AD and in APECED with adrenocortical failure, autoantibodies
recognize the p450c21 steroidogenic enzyme. Interestingly, in this
disease complex CD8+ T cells that reach against speciﬁc T cell
epitopes in p450c21 has been demonstrated (Bratland et al., 2009;
Rottembourg et al., 2010) Likewise, in thyroid diseases, thyroglob-
ulin and thyroid peroxidase are recognized by the autoantibodies,
irrespective if the condition is occurring alone, in association of
APS-2 or as part of the APECED complex. The similar syner-
gism in terms of the nature of autoantigens occurs in chronic
immunological liver diseases, too.
In chronic aggressive hepatitis the lymphocytic inﬁltrating cell
population has been shown to be of the CD8+ lineage (Si et al.,
1984). In a murine model of Graves’ disease, the CD8+ cell
population contains also the recently identiﬁed CD8+CD122+
T cells that are functionally similar to the CD4+CD25+ regulatory
T cells (Ryan et al., 2005). Furthermore, studies in thyroid and
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other affected organs show that one of the main cell population
in the lymphocytic inﬁltrate are in fact the CD4+ Th17 cells that
secrete as effector molecules, the cytokines IL-17 and IL-22. In
experimental autoimmune diseases, the balance between the Th17
effector cells and the two regulatory T cells, CD8+CD122+ and
CD4+CD25+, seems to regulate both the occurrence and severity
of tissue destruction and functional failure.
There could thus be two distinct mechanisms operating in the
pathogenesis of autoimmunity in the endocrinopathies: onemedi-
ated by soluble effector molecules, such as IL-17 and IL-22 as
well as type I interferons, and an other one mediated by effector
T cells, which are either of the CD8+ CTL cell or of the Th17 effec-
tor cell lineage. To counteract these, again two distinct biological
processes would occur: the production of autoantibodies and sec-
ondly, the emergency of the regulatory T cells. As to the regulatory
T cell response, it is to note that one key immunological failure in
APECED, is the dysregulation of the Treg cell maturation (Ryan
et al., 2005; Kekäläinen et al., 2007; Saitoh et al., 2007; Laakso et al.,
2010, 2011; Wolff et al., 2010).
In normal thymus, Treg maturation follows a prepro-
grammed scheme, and the immature CD8+CD4+FOXP3+
seems to be prone to apoptosis, whereas the more mature
form CD4+CD8−FOXP3+ cells form the active Treg popula-
tion (Lehtoviita et al., 2009). According to Endharti et al. (2011)
the CD8+CXCR3+ Tregs in humans are functionally similar to
murine CD8+CD122+ Tregs. Furthermore, in APECED patients
the recent thymic emigrant (RTE)pool of Treg cells shift to the acti-
vated pool and the RTE reservoir is depleted. Most importantly,
in APECED patients these cells express less FOXP3 than in the
healthy controls (Laakso et al., 2010). Thus, in APECED the newly
formed Treg cells have a developmental defect and their function is
therefore impaired. Data concerning the CD8+ regulatory T cells
in APECED patients is missing, however.
The ﬁnding that the regulatory T cell population in APECED is
functionally defective and that the expression of the key molecule
for Treg function, the FOXP3 is impaired, is consistent with clini-
cal ﬁndings in IPEX syndrome, caused by a defect in the function
of the FOXP3 gene. However, it should be noted that the effect of
FOXP3 mutations in Treg population also in the IPEX patients is
highly variable. Also, in contrast to APECED there seems to be a
genotype–phenotype correlation in IPEX, as different mutations
are associated in variable clinical picture, that show differences
in severity as well in the types of clinical components that are
present (Torgerson et al., 2007; d’Hennezel et al., 2009) A consis-
tent ﬁnding in IPEX is however the inability of the CD4+CD25
high Tregs to suppress the function of autologous effector T cells
(Bacchetta et al., 2006). There are, thus, several differences in the
clinical picture of APECED and IPEX, but both conditions show
clear immune destruction of at least some endocrine organs. Both
conditions also share some similarities in the GI symptoms.
The proposed hypothesis that in APECED both tissue destruc-
tive mechanisms and controlling regulatory mechanisms exist
raises a question whether APECED could be treated or even
cured by immunological manipulations. To ﬁnd an answer for
this question is one of the further challenges for APECED research
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